Apremilast (Otezla) is an oral phosphodiesterase 4 (PDE4) inhibitor. By regulating the intracellular levels of inflammatory mediators, it provides an innovative treatment option for a variety of immune-mediated diseases. Since its first approval in the United States in 2014, its unique mechanism of action and broad application scope have made it an important tool in clinical treatment.

Indications for Apremilast (Otezla)

Indications for Adult Patients

Active Psoriatic Arthritis: Indicated for adult patients diagnosed with active psoriatic arthritis.

Plaque Psoriasis: Indicated for adult patients who are candidates for phototherapy or systemic therapy.

Behçet’s Disease-Associated Oral Ulcers: Specifically indicated for the treatment of active oral ulcers in adults with Behçet’s disease.

Indications for Pediatric Patients (Aged 6 Years and Older with Body Weight ≥ 20 kg)

Active Psoriatic Arthritis: Indicated for pediatric patients who meet the diagnostic criteria.

Moderate to Severe Plaque Psoriasis: Indicated for pediatric patients who are candidates for phototherapy or systemic therapy.

Dosage Strengths and Physical Characteristics of Apremilast (Otezla)

10 mg Tablets

Color Characteristic: Pink tablets.

Marking System: Engraved with "APR" on one side and "10" on the other side.

20 mg Tablets

Color Characteristic: Brown tablets.

Marking System: Engraved with "APR" on one side and administration instructions on the other side.

30 mg Tablets

Color Characteristic: Beige tablets.

Marking System: Engraved with "APR" on one side and "30" on the other side.

Storage Instructions for Apremilast (Otezla)

Storage Temperature

Temperature Control: Must be stored in an environment below 30°C (86°F).

Packaging System

28-Day Initial Treatment Package: Contains 4 tablets of 10 mg, 4 tablets of 20 mg, and 47 tablets of 30 mg.

Standard Bottle Specification: 60-tablet bottle.

Administration and Management Specifications

Administration Method: Swallow the tablets whole; do not crush, split, or chew.